Abstract: The present disclosure provides compositions comprising decontaminating compounds, and pharmaceutically acceptable salts thereof and methods of treating or preventing a contamination in a mammal, in particular, the composition can include a mixture of polyvinyl acetate and povidone, a coblock polymer of ethylene oxide and propylene oxide, a polyvinyl alcohol, or combinations thereof, and an aqueous suspending agent.

Abstract: The present disclosure provides compositions comprising decontaminating compounds, and pharmaceutically acceptable salts thereof and methods of treating or preventing a contamination in a mammal, in particular, the composition can include a mixture of polyvinyl acetate and povidone, a cobloek polymer of ethylene oxide and propylene oxide, a polyvinyl alcohol, or combinations thereof, and an aqueous suspending agent.

Abstract: A composition and method are provided for alleviating the dermatological signs of intrinsic and extrinsic aging. A topical formulation containing a cosmeceutically active base, wherein the formulation provides a pH in the range of about 8.0 to 13.0 at the skin surface, is applied to the skin in order to prevent or treat aging-related skin conditions such as wrinkles, dry skin, age spots, sun damage (particularly UV radiation-induced oxidative stress), blemishes, hyperpigmented skin, age spots, increased skin thickness, loss of skin elasticity and collagen content, dry skin, lentigines and melasmas. The cosmeceutically active base is either an inorganic base, such as an inorganic hydroxide, an inorganic oxide, or a metal salt of a weak acid, or an organic base, particularly a nitrogenous base such as may be selected from primary amines, secondary amines, tertiary amines, amides, oximes, nitrites, aromatic and non-aromatic nitrogen-containing heterocycles, urea, and mixtures thereof.

Abstract: Provided are methods and topical pharmaceutical formulations for the treatment of inflammatory dermatoses. The invention involves the topical administration of a pharmacologically active base in a formulation having a pH of about 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations are particularly suited to the treatment of acne vulgaris.

Abstract: Methods and topical pharmaceutical formulations are provided for the treatment of nail fungus (onychomycosis). The invention involves a pharmacologically active antifungal agent, plus a pharmaceutically acceptable base in a formulation having a pH of 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations permeate the nail and are effective in treating fungal infections of the nail and surrounding tissues.

Abstract: Provided are methods and topical pharmaceutical formulations for use in the treatment of warts. The invention involves the topical administration of a pharmacologically active base in a formulation having a pH of about 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations can be used to treat human papilloma virus infections, particularly cutaneous warts.

Abstract: Provided are methods and topical pharmaceutical formulations for skin lightening. The invention involves the topical administration of a pharmacologically active base in a formulation having a pH of about 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations can be used to treat regions of hyperpigmented skin, comprising, as examples, age spots, freckles, disease-related hyperpigmented skin, melasma related to pregnancy or the use of oral contraceptives, and hyperpigmented skin due to chemical exposure or ingestion.

Abstract: Provided are methods and topical pharmaceutical formulations for use in the treatment of warts. The invention involves the topical administration of a pharmacologically active base in a formulation having a pH of about 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations can be used to treat human papilloma virus infections, particularly cutaneous warts.

Abstract: Provided are methods and topical pharmaceutical formulations for the treatment of inflammatory dermatoses. The invention involves the topical administration of a pharmacologically active base in a formulation having a pH of about 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations are particularly suited to the treatment of acne vulgaris.

Abstract: Provided are methods and topical pharmaceutical formulations for skin lightening. The invention involves the topical administration of a pharmacologically active base in a formulation having a pH of about 8.0 to about 13.0, preferably about 8.0 to 11.5, more preferably about 8.5 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations can be used to treat regions of hyperpigmented skin, comprising, as examples, age spots, freckles, disease-related hyperpigmented skin, melasma related to pregnancy or the use of oral contraceptives, and hyperpigmented skin due to chemical exposure or ingestion.

Abstract: Methods and topical pharmaceutical formulations are provided for the treatment of nail fungus (onychomycosis). The invention involves a pharmacologically active antifungal agent, plus a pharmaceutically acceptable base in a formulation having a pH of 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations permeate the nail and are effective in treating fungal infections of the nail and surrounding tissues.

Abstract: A composition and method are provided for alleviating the dermatological signs of intrinsic and extrinsic aging. A topical formulation containing a cosmeceutically active base, wherein the formulation provides a pH in the range of about 8.0 to 13.0 at the skin surface, is applied to the skin in order to prevent or treat aging-related skin conditions such as wrinkles, dry skin, age spots, sun damage (particularly UV radiation-induced oxidative stress), blemishes, hyperpigmented skin, age spots, increased skin thickness, loss of skin elasticity and collagen content, dry skin, lentigines and melasmas. The cosmeceutically active base is either an inorganic base, such as an inorganic hydroxide, an inorganic oxide, or a metal salt of a weak acid, or an organic base, particularly a nitrogenous base such as may be selected from primary amines, secondary amines, tertiary amines, amides, oximes, nitrites, aromatic and non-aromatic nitrogen-containing heterocycles, urea, and mixtures thereof.

Abstract: Provided is a topical pharmaceutical composition for the treatment of inflammatory dermatoses, including acne vulgaris, together with methods for its use. The composition and methods involve the topical use of an active agent effective in the treatment of inflammatory dermatoses plus a permeation-enhancing base that, in one embodiment, gives the composition a pH of about 8.0 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5.

Abstract: Provided is a topical pharmaceutical composition for the treatment of warts, together with methods for its use. The composition and methods involve the topical use of an active agent effective in the treatment of warts plus a permeation-enhancing base that, in one embodiment, gives the composition a pH of about 8.0 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. This composition can be used to treat human papilloma virus infections, particularly cutaneous warts.

Abstract: Provided is a topical pharmaceutical composition for skin lightening, which is particularly useful in treating skin hyperpigmentation, together with methods for its use. The composition and methods involve the topical use of an active agent effective in the treatment of skin hyperpigmentation plus a permeation-enhancing base that, in one embodiment, gives the composition a pH of about 8.0 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5.

Abstract: A composition and method are provided for alleviating the dermatological signs of intrinsic and extrinsic aging. A topical formulation containing a cosmeceutically active base, wherein the formulation has a pH in the range of about 7.5 to 13.0, is applied to the skin in order to prevent or treat aging-related skin conditions such as wrinkles, dry skin, age spots, sun damage (particularly UV radiation-induced oxidative stress), blemishes, hyperpigmented skin, age spots, increased skin thickness, loss of skin elasticity and collagen content, dry skin, lentigines and melasmas. The cosmeceutically active base is either a hydroxide-releasing agent, such as an inorganic hydroxide, an inorganic oxide, or a metal salt of a weak acid, or is an organic base, particularly a nitrogenous base.